Discussing his outlook on pharma names, Pal said that he expects only a 10-12 percent growth in Lupin‘s stock. Rating agencies Credit Suisse and Nomura had upgraded their ratings on the stock recently.
first published: Sep 24, 2015 12:08 pm
A collection of the most-viewed Moneycontrol videos.
Live: Market breadth weakens, India VIX jumps as Iran-US ceasefire hangs | Closing Bell
IEX Stock Crash Explained | CERC’s New Rule Shakes Power Market
LIVE | US Navy seizes Iranian ship; talks uncertain; Nifty 200 DMA key, bank earnings focus now!
Iran Rejects US Talks Again, Strait Of Hormuz Tensions Rise As Oil Route Risks Grow
